Cargando…
Sembragiline in Moderate Alzheimer’s Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD)
Background: Sembragiline is a potent, selective, long-acting, and reversible MAO-B inhibitor developed as a potential treatment for Alzheimer’s disease (AD). Objective: To evaluate the safety, tolerability, and efficacy of sembragiline in patients with moderate AD. Methods: In this Phase II study (N...
Autores principales: | Nave, Stephane, Doody, Rachelle S., Boada, Mercè, Grimmer, Timo, Savola, Juha-Matti, Delmar, Paul, Pauly-Evers, Meike, Nikolcheva, Tania, Czech, Christian, Borroni, Edilio, Ricci, Benedicte, Dukart, Juergen, Mannino, Marie, Carey, Tracie, Moran, Emma, Gilaberte, Inma, Muelhardt, Nicoletta Milani, Gerlach, Irene, Santarelli, Luca, Ostrowitzki, Susanne, Fontoura, Paulo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5523913/ https://www.ncbi.nlm.nih.gov/pubmed/28550255 http://dx.doi.org/10.3233/JAD-161309 |
Ejemplares similares
-
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
por: Ostrowitzki, Susanne, et al.
Publicado: (2017) -
Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
por: Ostrowitzki, Susanne, et al.
Publicado: (2018) -
Ultra-sensitive and high-throughput CRISPR-p owered COVID-19 diagnosis
por: Huang, Zhen, et al.
Publicado: (2020) -
Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design
por: Jain, Raksha, et al.
Publicado: (2022) -
Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer’s disease and elderly controls after oral administration of sembragiline
por: Sturm, Stefan, et al.
Publicado: (2016)